



- Name and address of employer
- Main activity and responsibility
- Occupation or position held

**Università di Roma "La Sapienza" Institute of Virology Rome Italy**  
**Working on picornavirus molecular biology**  
**Internal Researcher**

## EDUCATION AND TRAINING

- Dates ) **2014-2018**
- Name and type of organization providing education and training **MIUR**  
*Italy*
- Principal subjects / occupational skills covered **Virology**
- Type of qualification awarded **Full Professor Microbiology [National Habilitation (06/A3) 2014-2018]**
- Dates ) **06-1998/01-1999**
- Name and type of organization providing education and training **Lab. of Immunology Queensland University - -**  
*Brisbane Australia*
- Principal subjects / occupational skills covered **HPV vaccine**
- Type of qualification awarded **FIRC fellow**
- Dates ) **01-1988/12-1989**
- Name and type of organization providing education and training **Beatson Institute - Glasgow - Scotland**
- Principal subjects / occupational skills covered **HPV cancerogenesis and diagnosis**
- Type of qualification awarded **AIRC fellow**
- Dates ) **01-1984/05-1985**
- Name and type of organization providing education and training **INDIANA University - Bloomington, USA**
- Principal subjects / occupational skills covered **cloning of enterovirus**
- Type of qualification awarded **Research Associate**
- Dates ) **01-1983/12-1985**
- Name and type of organization providing education and training **Università di Roma "La Sapienza" - Institute of**  
*Virology*
- Principal subjects / occupational skills covered **molecular biology and virology**
- Type of qualification awarded **PhD**
- Dates ) **01-1980/12-1983**
- Name and type of organization providing education and training **Università di Roma "La Sapienza" – Clinical Pathology School**
- Principal subjects / occupational skills covered **Clinical Pathology**
- Type of qualification awarded **clinical pathology Specialist**
- Dates ) **09-1973/07-1979**
- Name and type of organization providing education and training **Università di Roma "La Sapienza" - Institute of**  
*Virology*
- Principal subjects / occupational skills covered **medical degree, virology**
- Type of qualification awarded **MD**

**PERSONAL SKILL AND  
COMPETENCES**

*Acquisite nel corso della vita e della  
carriera ma non necessariamente  
riconosciute da certificati e diplomi  
ufficiali.*

MOTHER TONGUE

**Italian**

OTHER LANGUAGES

**English**

Understanding

excellent.

• Writing

excellent.

• Speaking

excellent.

**FRANCAIS**

Understanding

EXCELLENT.

• Writing

GOOD.

• Speaking

GOOD.

## TECHNICAL SKILLS AND COMPETENCE

As Chief of HPV-Unit the mission was to formalize an organizational model of a "unified and coordinated space" in which originate jointly initiatives related to the topic of HPV: the clinical management (diagnosis and treatment guidelines, facilitated routes and more), and the scientific matching (creation of ad hoc database, sharing of researches and more). This organizational model is a tool to inform, train and network both patients and health workers involved in HPV-related pathologies, from gynaecological area to the skin, comprising ENT, urological and proctologic diseases. Regarding tumor prevention, HPV vaccination, that is a program already started in 2014 for female, up to 45 years old, and later on extended to male, Dr. Venuti is in charge to render fully operating this preventive tool with a constant increase of vaccinated people both women and men. Dr. Venuti is actively involved in scientific activities focused on translational researches of virus-associated cancers, on cancer prevention and on the development of permanent professional training facilities and information addressed to the citizens

The training activity is scheduled with courses for HCWs while the activity of user's information is constantly carried out by telephone, by email and through the continuous up-grading the dedicated internet site. In addition dedicated course and Meetings were organized by Dr. Venuti, the last three Meeting on cancer prevention were: "OPEN DAY. Difendiamoci dai Tumori: *Prevenzione & Informazione*" (Roma 10-12-2016); "10 Anni di Vaccinazione HPV" (Rome - 03-25-2017) HPV Related Diseases: Diagnostic and therapeutic strategies (28-11-2019)

He has been and is scientific responsible of many Projects on HPV granted by CNR-ACRO, AIRC, Ministry of Health, Abbott Co. USA, Compagnia di San Paolo Torino, Fraunhofer Institute (USA), MSD (Europe), Roche (Europe), Lega Italiana Tumori (LILT).

### Teaching activity:

1984 He was lecturer in a course for graduate student at the Dept. of Biology INDIANA University. 1999-2007 he was teaching at the Corso di Laurea in Infermiere Generico e Pediatrico University "La Sapienza" -Rome and 2003-2008 he was giving integrate teaching activity at the Faculty of Veterinary, University "Federico II" Naples. 2007-2012 he was giving integrate teaching activity at the Faculty of Medicine and Psychology University "La Sapienza" - Rome. Since 2012 he was teaching HPV molecular biology at Course Master in Virology University "La Sapienza" -Rome

### Editorial Board Membership:

Since 2006 is Board member of the Journal of Exp. and Clin. Cancer Research

### Patents:

- National (Italy) on Vaccini a subunità e procedimenti per la loro produzione RM2001A000332, International (USA and EUROPE) on Subunit vaccines and processes for the production thereof. #PCT/IT02/00354; National (Italy) on Vaccini basati su chimere genetiche tra antigeni virali/tumorali (es. HPV) e proteine vegetali (es. RIPs). Submitted C-08/05.

He is author of 124 publications on peer reviewed Journals with Total IF **435.507** and h index **31**.

## Publications (LAST 5 YEARS)

- 1: Falcucci S, Paolini F, Mileo AM, Franconi R, Massa S, Rinaldi A, Venuti A. ePCL Electrospun Microfibrous Layers for Immune Assays: Sensitive ELISA for the Detection of Serum Antibodies Against HPV16 E7 Oncoprotein. *ACS Omega*. 2021 Mar 26;6(13):8778-8783. doi: 10.1021/acsomega.0c03976.
- 2: Krasniqi E, Barba M, Venuti A, Pizzuti L, Cappuzzo F, Landi L, Carpano S, Marchetti P, Villa A, Vizza E, Giuliano G, Mazzotta M, Marinelli D, Gnignera S, Vincenzoni C, Stranges V, Sergi D, Giordano A, Tomao F, Maugeri-Saccà M, Sanguineti G, Di Lisa FS, Tomao S, Ciliberto G, Vici P. Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. *J Clin Med*. 2021 Apr 6;10(7):1525. doi: 10.3390/jcm10071525.
- 3: Cristalli G, Venuti A, Giudici F, Paolini F, Ferrel F, Mercante G, Spriano G, Boscolo Nata F. HPV Infection in Middle Ear Squamous Cell Carcinoma: Prevalence, Genotyping and Prognostic Impact. *J Clin Med*. 2021 Feb 12;10(4):738. doi: 10.3390/jcm10040738.
- 4: Paolini F, Amici C, Carosi M, Bonomo C, Di Bonito P, Venuti A, Accardi L. Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors. *J Exp Clin Cancer Res*. 2021 Jan 23;40(1):37. doi: 10.1186/s13046-021-01841-w.
- 5: Franconi R, Massa S, Paolini F, Vici P, Venuti A. Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers. *Cancers (Basel)*. 2020 Oct 23;12(11):3101. doi: 10.3390/cancers12113101.
- 6: Paolini F, Zaccarini M, Francesconi A, Mariani L, Muscardin L, Donati P, Venuti A. Beta HPV Type 15 Can Interfere With NF- $\kappa$ B Activity and Apoptosis in Human Keratinocytes. *Front Cell Infect Microbiol*. 2020 Mar 18;10:111. doi: 10.3389/fcimb.2020.00111.
- 7: Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. *Cancer Res*. 2020 Feb 15;80(4):732-746. doi: 10.1158/0008-5472.CAN-19-1771. Epub 2019
- 1: Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB. HPV16 E5 Mediates Resistance to PD-L1 Blockade and can be targeted with Rimantadine in Head and Neck Cancer. *Cancer Res*. 2019 Dec 17. pii: canres.1771.2019. doi: 10.1158/0008-5472.CAN-19-1771.
- 2: Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P. Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. *J Cancer*. 2019 Oct 12;10(24):5903-5914. doi: 10.7150/jca.35109. eCollection 2019. Review
- 3: Krasniqi E, Barchiesi G, Pizzuti L, Mazzotta M, Venuti A, Maugeri-Saccà M, Sanguineti G, Massimiani G, Sergi D, Carpano S, Marchetti P, Tomao S, Gamucci T, De Maria R, Tomao F, Natoli C, Tinari N, Ciliberto G, Barba M, Vici P. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. *J Hematol Oncol*. 2019 Oct 29;12(1):111. doi:10.1186/s13045-019-0798-2. Review.
- 4: Conforti C, Paolini F, Venuti A, Dianzani C, Zalaudek I. Comment on 'The detection rate of human papillomavirus in well-differentiated squamous cell carcinoma and keratoacanthoma: is there new evidence for a viral pathogenesis of keratoacanthoma?' - reply from authors. *Br J Dermatol*. 2019 Dec;181(6):1345-1346. doi: 10.1111/bjd.18385. Epub 2019 Oct 15
- 5: Conforti C, Paolini F, Venuti A, Dianzani C, Zalaudek I. The detection rate of human papillomavirus in well-differentiated squamous cell carcinoma and keratoacanthoma: is there new evidence for a viral pathogenesis of keratoacanthoma? *Br J Dermatol*. 2019 Dec;181(6):1309-1311. doi: 10.1111/bjd.18212. Epub 2019 Aug 13.
- 6: Massa S, Paolini F, Marino C, Franconi R, Venuti A. Bioproduction of a Therapeutic Vaccine Against Human Papillomavirus in Tomato Hairy Root Cultures. *Front Plant Sci*. 2019 Apr 11;10:452. doi: 10.3389/fpls.2019.00452. eCollection 2019.
- 7: Mora Román JJ, Del Campo M, Villar J, Paolini F, Curzio G, Venuti A, Jara L, Ferreira J, Murgas P, Lladser A, Manubens A, Becker M. Immunotherapeutic Potential of Mollusk Hemocyanins in Combination with Human Vaccine Adjuvants in Murine Models of Oral Cancer. *J Immunol Res*. 2019 Jan 20;2019:7076942. doi: 10.1155/2019/7076942. eCollection 2019.
- 8: Venuti A. Review of DNA tumour viruses. *Hum Vaccin Immunother*. 2019;15(5):1133-1134. doi: 10.1080/21645515.2019.1577677. Epub 2019 Mar 20.
- 9: Dotta L, Notarangelo LD, Moratto D, Kumar R, Porta F, Soresina A, Lougaris V, Plebani A, Smith CIE, Norlin AC, Gómez Raccio AC, Bubanska E, Bertolini P, Amendola G, Visentini M, Fiorilli M, Venuti A, Badolato R. Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies. *J Allergy Clin Immunol Pract*. 2019 May - Jun;7(5):1568-1577. doi: 10.1016/j.jaip.2019.01.045. Epub 2019 Feb 2.
- 10: Paolini F, Bonomo C, Terrenato I, Pennetti A, Covello R, Cristalli G, Venuti A. Beta human papillomaviruses in middle ear squamous cell carcinoma. *Oral Oncol*. 2019 Mar;90:134-135. doi: 10.1016/j.oraloncology.2019.01.004. Epub 2019 Jan 18.
- 11: Dianzani C, Paolini F, Conforti C, Silvestre M, Flagiello F, Venuti A. Human papillomavirus in skin tags: a case series. *Dermatol Pract Concept*. 2018 Oct 31;8(4):295-296. doi: 10.5826/dpc.0804a08. eCollection 2018 Oct.
- 12: Barros MR Jr, de Melo CML, Barros MLCMGR, de Cássia Pereira de Lima R, de Freitas AC, Venuti A. Activities of stromal and immune cells in HPV-related cancers. *J Exp Clin Cancer Res*. 2018 Jul 5;37(1):137. doi: 10.1186/s13046-018-0802-7. Review.
- 13: Barros MR Jr, de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers. *J Immunol Res*. 2018 May 2;2018:2912671. doi:10.1155/2018/2912671. eCollection 2018. Review.
- 14: Cordeiro MN, De Lima RCP, Paolini F, Melo ARDS, Campos APF, Venuti A, De Freitas AC. Current research into novel therapeutic vaccines against cervical cancer. *Expert Rev Anticancer Ther*. 2018 Apr;18(4):365-376. doi:10.1080/14737140.2018.1445527
- 15: Wu R, Paolini F, Frank D, Kamdar D, Curzio G, Pichi B, Pellini R, Spriano G, Bonagura VR, Venuti A, Steinberg BM. Latent human papillomavirus type 16 infection is widespread in patients with oropharyngeal cancers. *Oral Oncol*. 2018 Mar;78:222-224. doi: 10.1016/j.oraloncology.2018.01.032. Epub 2018 Feb 9.
- 16: Dianzani C, Paolini F, Conforti C, Riva E, Beninati E, Venuti A. Human papilloma virus expression in immunocompetent patients with actinic keratosis: A case series. *J Am Acad Dermatol*. 2017 Oct;77(4):770-772. doi:10.1016/j.jaad.2017.05.035.
- 17: de Freitas AC, de Oliveira THA, Barros MR Jr, Venuti A. hrHPV E5 oncoprotein: immune evasion and related immunotherapies. *J Exp Clin Cancer Res*. 2017 May 25;36(1):71. doi: 10.1186/s13046-017-0541-1. Review.

## Publications (LAST 5 YEARS)

- 18: Curzio G, Paolini F, Cota C, Donati P, Di Mattia C, Mariani L, Migliano E, Venuti A. Merkel cell carcinoma: new insights into pathogenesis. *Eur J Dermatol*. 2017 Jun 1;27(3):307-309. doi: 10.1684/ejd.2017.2974.
- 19: Massa S, Paolini F, Curzio G, Cordeiro MN, Illiano E, Demurtas OC, Franconi R, Venuti A. A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines. *Hum Vaccin Immunother*. 2017 Feb;13(2):271-282. doi: 10.1080/21645515.2017.1264766. Epub 2017 Jan 24.
- 20: Paolini F, Curzio G, Cordeiro MN, Massa S, Mariani L, Pimpinelli F, de Freitas AC, Franconi R, Venuti A. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy. *Hum Vaccin Immunother*. 2017 Feb;13(2):291-297. doi: 10.1080/21645515.2017.1264777. Epub 2016 Dec 8.
- 21: Illiano E, Bissa M, Paolini F, Zanotto C, De Giulii Morghen C, Franconi R, Radaelli A, Venuti A. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X. *Virus Res*. 2016 Oct 2;225:82-90. doi: 10.1016/j.virusres.2016.09.011. Epub 2016 Sep 21.
- 22: Illiano E, Demurtas OC, Massa S, Di Bonito P, Consalvi V, Chiaraluce R, Zanotto C, De Giulii Morghen C, Radaelli A, Venuti A, Franconi R. Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: implications for HPV-tumor diagnosis and therapy. *J Transl Med*. 2016 Jul 28;14(1):224. doi: 10.1186/s12967-016-0978-6.
- 23: Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Saccà M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. *Expert Rev Vaccines*. 2016 Oct;15(10):1327-36. doi: 10.1080/14760584.2016.1176533. Epub 2016 May 9. Review.
- 24: Paolini F, Curzio G, Melucci E, Terrenato I, Antoniani B, Carosi M, Mottolese M, Vici P, Mariani L, Venuti A. Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions. *Eur J Cancer*. 2016 May;58:52-61. doi: 10.1016/j.ejca.2016.02.001. Epub 2016 Mar 7.
- 25: Amici C, Visintin M, Verachi F, Paolini F, Percario Z, Di Bonito P, Mandarino A, Affabris E, Venuti A, Accardi L. A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models. *Oncotarget*. 2016 Mar 29;7(13):15539-53. doi: 10.18632/oncotarget.6925.
- 26: Paolini F, Cota C, Amantea A, Curzio G, Venuti A. Mucosal Alpha-Papillomavirus (HPV89) in a rare skin lesion. *Virology*. 2015 Jul 7;12:105. doi: 10.1186/s12985-015-0336-y
- 27: Venuti A, Curzio G, Mariani L, Paolini F. Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models. *Cancer Immunol Immunother*. 2015 Oct;64(10):1329-38. doi: 10.1007/s00262-015-1734-0. Epub 2015 Jul 3. Review.
- 28: Bissa M, Illiano E, Pacchioni S, Paolini F, Zanotto C, De Giulii Morghen C, Massa S, Franconi R, Radaelli A, Venuti A. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. *J Transl Med*. 2015 Mar 5;13:80. doi: 10.1186/s12967-015-0437-9.
- 29: Bissa M, Zanotto C, Pacchioni S, Volonté L, Venuti A, Lembo D, De Giulii Morghen C, Radaelli A. The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response. *Antiviral Res*. 2015 Apr;116:67-75. doi: 10.1016/j.antiviral.2015.01.012. Epub 2015 Feb 7.
- 30: Cordeiro MN, Paolini F, Massa S, Curzio G, Illiano E, Duarte Silva AJ, Franconi R, Bissa M, Morghen C de G, de Freitas AC, Venuti A. Anti-tumor effects of genetic vaccines against HPV major oncogenes. *Hum Vaccin Immunother*. 2015;11(1):45-52. doi: 10.4161/hv.34303. Epub 2014 Nov 1.

Date 30-08-2021

Signature \_\_\_\_\_



Aldo Venuti